Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

Key Insights

• Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient.
• The clinical assessment is led by Dr. Alan Irvine, a leading dermatologist, aiming to broaden the data set for QRX003 and potentially lower the eligibility age for treatment.
• QRX003 is currently in late-stage clinical trials with promising data showing improvement across multiple endpoints and no treatment-related adverse events in older patients.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has commenced clinical testing of its lead product, QRX003, in a young child diagnosed with Netherton Syndrome (NS). This rare, inherited genetic disorder currently lacks an approved treatment or cure, making this a significant step forward.

The clinical assessment is being conducted at Children's Health Ireland in Dublin, under the guidance of Dr. Alan Irvine, a consultant dermatologist and professor at Trinity College Dublin. Dr. Irvine's extensive experience in epithelial genetics and his role as president of the International Eczema Council position him as a key figure in this evaluation.

Clinical Significance and Expansion

Dr. Michael Myers, CEO of Quoin, emphasized the importance of this initiative, stating, "We are pleased to announce this latest initiative for Quoin as we strive to generate the broadest and most diverse data set possible for QRX003 in Netherton Syndrome patients." The company hopes that the data from this assessment will support lowering the eligibility age for QRX003 treatment. Plans are underway to broaden the clinical assessment to include three additional pediatric subjects in Spain.

QRX003: A Potential Treatment for Netherton Syndrome

QRX003 is Quoin's most advanced product in development and is currently being evaluated in two late-stage clinical trials. The trials are being conducted under an open Investigational New Drug application with the U.S. Food and Drug Administration. To date, clinical data has been promising, with all evaluable subjects showing improvement across a number of endpoints and no treatment-related adverse events recorded. In addition to the five open clinical sites in the United States, a sixth site is opening in Saudi Arabia, and two additional clinical sites are planned to open in the United Kingdom.

About Netherton Syndrome and QRX003

Netherton Syndrome is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene, leading to severe skin barrier defects, recurring infections, and a predisposition to allergies, asthma, and eczema. Patients often suffer from severe dehydration, chronic skin inflammation, and stunted growth. QRX003 is a topical lotion formulated with a proprietary delivery technology containing a broad-spectrum serine protease inhibitor, designed to normalize skin-shedding and strengthen the skin barrier by performing the function of the LEKTI protein, which is absent in Netherton patients.